 |
|
Zinc finger proteins put personalized HIV therapy within reach
July 01, 2008Penn researchers modify T-cell receptor gene to develop new type of AIDS treatment
PHILADELPHIA - Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.
The Penn researchers and colleagues from Sangamo Biosciences (Nasdaq:SGMO), Richmond, CA, who developed the zinc finger technology, report in an advanced online issue of Nature Biotechnology the first steps towards the goal of using modified T cells from an HIV-infected person for their own treatment. They showed that, using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.
"By inducing mutations in the CCR5 gene using zinc finger proteins, we've reduced the expression of CCR5 surface proteins on T cells, which is necessary for the AIDS virus to enter these immune system cells," explains first author Elena Perez, MD, PhD, Assistant Professor of Pediatrics at Penn. "This approach stops the AIDS virus from entering the T cells because it now has an introduced error into the CCR5 gene."
Some people are born with a mutation on their CCR5 gene and therefore do not have a working CCR5 receptor on the surface of their T cells. These rare individuals are immune to HIV infection and seemingly are not affected by the non-functional CCR5 protein. The zinc finger approach aims to mimic this natural immunity.
Perez performed the research while a postdoctoral fellow in the lab of senior author Carl June, MD, Director of Translational Medicine at the Abramson Family Cancer Research Institute, and a Professor of Pathology and Laboratory Medicine at Penn. Perez is also an attending physician with the Children's Hospital of Philadelphia in the Division of Allergy and Immunology.
Normally, zinc fingers bind to different bases in the DNA sequence to regulate the activity of genes. The zinc fingers used in this experiment were designed to bind to specific DNA sequences in the CCR5 gene. The CCR5 protein is one of the two cell-surface receptors needed for HIV to gain entry into a T cell in order to replicate.
In this study, the zinc finger protein brings a DNA enzyme to the CCR5 gene to cut a portion of its sequence, but due to the repair process a new mutation arises in the CCR5 protein, rendering it non-functional. Without a functional CCR5 protein on the cell's surface, HIV cannot enter, presumably leading to resistance to HIV infection.
The researchers demonstrated this process in cell culture and in a mouse model. For the animal part of the study, the investigators used healthy human CD4 T cells and added DNA that expresses the zinc fingers, which modifies the CCR5 co-receptor. They grew the engineered cells in tissue culture flasks and transferred them into immune-deficient mice infected with HIV. "We followed them over time and showed that those mice that received the zinc-finger-treated cells showed less viral load than controls and improved CD4 counts," says Perez.
The researchers are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene deliberately knocked out. These modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.
University of Pennsylvania School of Medicine
"By inducing mutations in the CCR5 gene using zinc finger proteins, we've reduced the expression of CCR5 surface proteins on T cells, which is necessary for the AIDS virus to enter these immune system cells," explains first author Elena Perez, MD, PhD, Assistant Professor of Pediatrics at Penn. "This approach stops the AIDS virus from entering the T cells because it now has an introduced error into the CCR5 gene."
Some people are born with a mutation on their CCR5 gene and therefore do not have a working CCR5 receptor on the surface of their T cells. These rare individuals are immune to HIV infection and seemingly are not affected by the non-functional CCR5 protein. The zinc finger approach aims to mimic this natural immunity.
Perez performed the research while a postdoctoral fellow in the lab of senior author Carl June, MD, Director of Translational Medicine at the Abramson Family Cancer Research Institute, and a Professor of Pathology and Laboratory Medicine at Penn. Perez is also an attending physician with the Children's Hospital of Philadelphia in the Division of Allergy and Immunology.
Normally, zinc fingers bind to different bases in the DNA sequence to regulate the activity of genes. The zinc fingers used in this experiment were designed to bind to specific DNA sequences in the CCR5 gene. The CCR5 protein is one of the two cell-surface receptors needed for HIV to gain entry into a T cell in order to replicate.
In this study, the zinc finger protein brings a DNA enzyme to the CCR5 gene to cut a portion of its sequence, but due to the repair process a new mutation arises in the CCR5 protein, rendering it non-functional. Without a functional CCR5 protein on the cell's surface, HIV cannot enter, presumably leading to resistance to HIV infection.
The researchers demonstrated this process in cell culture and in a mouse model. For the animal part of the study, the investigators used healthy human CD4 T cells and added DNA that expresses the zinc fingers, which modifies the CCR5 co-receptor. They grew the engineered cells in tissue culture flasks and transferred them into immune-deficient mice infected with HIV. "We followed them over time and showed that those mice that received the zinc-finger-treated cells showed less viral load than controls and improved CD4 counts," says Perez.
The researchers are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene deliberately knocked out. These modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.
University of Pennsylvania School of Medicine
HIV Therapy Current Events and HIV Therapy News RSSU of M study shows why treatment isn't effective for HIV
University of Minnesota researchers have answered a key question as to why antiretroviral therapy isn't effective in restoring immunity in HIV-infected patients.
Findings offer insights into role of breastfeeding in preventing infant death, HIV infection
In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk-or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy.
Study shows suppressing herpes virus may reduce infectiousness of HIV
A recent study of men co-infected with herpes simplex virus type 2 (HSV-2) and HIV revealed that drugs used to suppress HSV decrease the levels of HIV in the blood and rectal secretions, which may make patients less likely to transmit the virus.
HIV patients sicker when seeking care than in the past
It was hoped that as HIV treatment improved and as HIV-related public health initiatives encouraged people to be tested for the disease and seek care, that HIV-infected patients would seek care quickly.
Studies affirm need for influenza and measles vaccinations in HIV-infected patients
Two new studies emphasize the importance of delivering measles and influenza vaccines to HIV-infected individuals. Both studies are published in the August 1 issue of The Journal of Infectious Diseases, now available online.
New treatment model for HIV
Treatment of HIV patients must balance the need to suppress viral replication against the harmful side effects and significant cost to the patient of antiretroviral therapy.
Widely used hepatitis B drug spurs HIV drug resistance
A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV.
HIV-1 kills immune cells in the gut that may never bounce back
People with HIV have been living longer, healthier lives since the development of highly active antiretroviral therapy (or HAART) in 1995. In fact, most patients on the drug regimen do so well that, according to blood tests, their immune cells appear to return to pre-HIV levels.
UT Southwestern researchers refocus studies on patients with HIV, hepatitis
As HIV patients live longer thanks to advanced therapies, researchers are looking for better ways to treat accompanying maladies such as hepatitis that traditionally were not emphasized.
UC Davis study finds HIV hiding from drugs in gut, preventing immune recovery
UC Davis researchers have discovered that the human immunodeficiency virus, the virus that causes AIDS, is able to survive efforts to destroy it by hiding out in the mucosal tissues of the intestine.
More HIV Therapy Current Events and HIV Therapy News Articles
 | The Sanford Guide to HIV/AIDS Therapy (Sanfords Guides) by Jay P. Sanford As the AIDS epidemic continues to explode around the world with uncontrolled spread antiretroviral therapy for HIV in the western world, where drugs are readily available, continues to improve. But significant long-term metoabolic and peripheral nerve toxicities have now emerged as complicating problems. Care of the HIV-infected patient is becoming increasingly complicated and today most patients... |
| The Sanford Guide to HIV/AIDS Therapy 2009 by Merle Sande | |
 | Entry Inhibitors in HIV Therapy (Milestones in Drug Therapy) (Milestones in Drug Therapy) Entry Inhibitors in HIV Therapy presents the current status of this relatively new and highly dynamic class of inhibitors and provides a unique overview of obstacles and considerations for HIV entry inhibition compared to other antiretroviral targets. The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss... |
| Revised guidelines simplify HIV/AIDS therapy: 'preferred' and 'alternative' regimens.(Dermatologic Therapy): An article from: Skin & Allergy News by Robert Finn This digital document is an article from Skin & Allergy News, published by International Medical News Group on February 1, 2004. The length of the article is 594 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Infectious Disease) A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development... |
 | The Science, Spread, And Therapy of HIV Disease: Everything You Need to Know, but Had No Idea Who to Ask (Science Fundamentals, Vol. 1) by Michael A. Dispezio Uses a question and answer format to provide information about the disease of AIDS including its outbreak, basic biology, viruses, transmission, and methods for... |
 | HIV and AIDS Care (Therapy in Practice) by Louise Cusack, Surinder Singh |
 | Current Clinical Strategies Manual of HIV/AIDS Therapy 2003 Edition (Current Clinical Strategies) by Douglas C., M.D. Princeton Annual pocket covers clinical care of the HIV-infected patient. Second section covers opportunistic infections.... |
| The Sanford guide to antimicrobial therapy, 1996 ;: The Sanford guide to HIV/AIDS therapy, 1996 by Jay P Sanford | |
 | Expanding Access to Investigational Therapies for HIV Infection and AIDS by Roundtable for the Development of Drugs and Vaccines Against AIDS, Institute of Medicine The call for a "parallel track" for AIDS drug development--a proposal that would allow the early distribution of AIDS drugs to large numbers of patients in parallel with the conventional clinical trials that assess the drugs' safety and efficacy--has sparked controversy within the scientific community. Questions have arisen about the risks to patients of such a plan, about its potential effect on... |
| © 2008 BrightSurf.com |